Can brain MRI reveal more than BMI?

Performance was strong inside the training sources and lower outside them

UK Biobank, HCP and HCP-Aging supplied the development data. The researchers allocated 31,206 scans to training, 8,917 to validation and hyperparameter tuning, and 4,459 to a blind within-cohort test. Sampling during training deliberately reduced UK Biobank’s dominance by drawing replacement samples from the smaller cohorts in every epoch.

In the combined blind test, predicted and measured BMI had a Pearson correlation of 0.744. Performance differed by source: 0.752 in UK Biobank, 0.664 in HCP-Aging and 0.525 in HCP. Correlation does not tell readers whether errors are clinically acceptable, and a model can rank BMI reasonably while remaining inaccurate for an individual.

ADNI, PPMI and PREDICT-HD were held out from model development. Correlations in these external cohorts were only about 0.44–0.45. The authors point to differing scanners, pulse sequences, ages and study populations. These cohorts contained screened healthy controls from neurodegenerative-disease studies and skewed older, so they are useful tests of technical transfer but not representative clinical populations.

The drop is central to the story. A model can appear strong when test data share recruitment and acquisition patterns with development data, then lose performance when those conditions change. Before any health use, a frozen model would need evaluation across scanner manufacturers, protocols, hospitals, demographic groups and common image-quality problems.[1]

A longitudinal subset tested whether the signal could move

The study separately examined 3,009 UK Biobank participants with baseline and follow-up scans. The average interval was 2.3 years. To avoid direct leakage, the longitudinal participants were held out while a variant of the model trained on 41,573 people who had baseline imaging only.

Change in predicted BMI correlated with measured BMI change at r=0.43. The model was more sensitive to BMI gains than losses: the fitted slope for increases was about 54% larger. Tracking was also stronger among participants with obesity, where the correlation was 0.49, than among those in the healthy-weight category, where it was 0.37.

This suggests the MRI representation is not completely fixed, but it does not show that brain structure changed because BMI changed. The subgroup was observational, had one follow-up and contained very little average BMI change despite wide individual variation. Medication, illness, ageing, smoking, vascular factors and scanner effects could move both the image signal and body weight.[1]

Disease comparisons used one cohort and one form of internal validation

The disease analysis focused on 34,524 UK Biobank participants with clinical information. Eight conditions had at least 1% prevalence: atrial fibrillation or flutter, coronary artery disease, type 2 diabetes, hypercholesterolaemia, hypertension, myocardial infarction, heart failure and chronic obstructive pulmonary disease.

For each condition, the researchers fitted simple logistic-regression classifiers using either BMI or the model’s 64 MRI-derived features. Tenfold cross-validation split the same UK Biobank sample into training and test folds. The feature-based classifiers produced higher area-under-the-curve values than BMI-only classifiers for all eight conditions, with statistically significant paired comparisons. Post-hoc Brier scores examined calibration.

That comparison shows the learned representation contains information associated with disease beyond the single BMI number. It does not show that MRI should be used as a screening test. Disease classification was never evaluated in ADNI, PPMI, PREDICT-HD or another independent clinical cohort. The models were not optimised for absolute-risk prediction, and cross-validation within one resource cannot reveal how coding, prevalence or referral patterns change elsewhere.

The design also lacks a clinically relevant comparator. A real screening model would be judged against readily available age, sex, blood pressure, smoking history, laboratory results and existing risk scores—not BMI alone. Brain MRI is expensive and generally obtained for another clinical reason, so a modest statistical advantage over BMI would not justify population scanning.[1]

White-matter sensitivity is a clue, not a mechanism

Integrated gradients highlighted where changing voxel intensity would most affect the BMI estimate. Principal-component summaries of these maps emphasised distributed white-matter signals, including the corpus callosum, cerebellar pathways and brainstem. Similar feature projections also separated some disease groups.

These maps are model-attribution tools. They do not prove that a highlighted region is damaged, that it caused obesity or disease, or that the network discovered a new anatomical pathway. The authors explicitly describe the signals as sensitivity patterns rather than validated localisation. They did not test reliability across preprocessing choices, templates, architectures or repeated scans.

Inflammation, cerebrovascular burden and shared genetic influences are plausible explanations discussed by the authors, but all remain hypotheses. Age, smoking and socioeconomic factors can affect both brain structure and cardiometabolic health. Covariate analyses reduce some alternative explanations; they cannot remove residual confounding from observational imaging data.[1]

Large data do not remove selection and purpose limits

UK Biobank’s scale is a strength and a source of bias. Volunteers are generally healthier, more educated and more affluent than the broader UK population. Its imaging participants are a further selected subset. A representation learned mainly from that group may behave differently in people with severe illness, disability, greater deprivation or different ancestry.

The other cohorts broaden scanner and age variation but were created for neuroscience and neurodegenerative research. Their participants, eligibility rules and imaging protocols were not designed to validate a general metabolic biomarker. Importantly, the external cohorts were used only for BMI prediction; the paper’s disease claims stayed entirely within UK Biobank.

The authors report no direct funding for the analysis and declare no competing interests. Several are affiliated with IBM Research, which is relevant institutional context even without a declared conflict. Parent datasets had their own public and private funders and access rules. Analysis code is public, but most participant-level imaging and health data require approval from the relevant repositories.[1][2]

What would turn an association into useful evidence

The next stage should freeze the representation and test disease classification in independent, population-representative cohorts with prespecified outcomes. Results should be reported by scanner, site, sex, age, ethnicity, socioeconomic position and disease prevalence, with calibration as well as discrimination. A benchmark should include conventional clinical variables and validated risk scores.

Longer follow-up could test whether the MRI signature predicts future disease after controlling for current risk factors, rather than merely recognising existing disease. Repeated scans would help separate stable anatomy from dynamic metabolic change. Reliability experiments should vary preprocessing and scanner conditions and measure whether the same person receives a consistent representation.

The practical conclusion is therefore restrained. Deep learning can extract a reproducible-looking BMI-related signal from large brain-imaging datasets, and that signal carries associations with systemic disease inside UK Biobank. It may help researchers study how brain and body health overlap. It is not a diagnosis, a causal explanation, a validated clinical risk score or a reason to order an MRI.[1][2]